Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. 8-K earnings release, 10-Q stay in one workspace.
Earnings call · FY2022 Q1
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Executive readout · one minute
Read the call alongside every captured source. 8-K earnings release, 10-Q stay in one workspace.
Forward guidance
5 guided metrics
Management's latest ranges and targets are included below.
Research coverage
2 live sources
Open each available source without leaving this research workspace.
Open the source you need; every reader stays inside this workspace.
From the 8-K filed May 3, 2022.
| Metric | Period | Guided | Basis | Actual |
|---|---|---|---|---|
|
Revenues
Lowered
2022
|
$15.4B – $16B | — | $14.93B below | |
|
COPAXONE revenues
2022
|
$750M | — | — | |
|
Adjusted EBITDA
2022
|
$4.7B – $5B | Non-GAAP | — | |
|
Non-GAAP diluted EPS
Maintained
2022
|
$2.40 – $2.60 | Non-GAAP | — | |
|
Free cash flow
Maintained
2022
|
$1.9B – $2.2B | — | — |
How the reported period landed and where the business moved.
SEC filing · Item 2.02
Filed May 3, 2022 · complete as-filed document
SEC periodic report
Filed May 3, 2022 · complete as-filed document